Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan
| Autor: | Toshihiro Tanaka, Hidenori Sasaki, Tohru Takata, Hisatomi Arima, Toshiki Maeda, Yasushi Takamatsu, Atsushi Togawa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Health Knowledge Attitudes Practice Cancer Research medicine.medical_specialty 2019-20 coronavirus outbreak Influenza vaccine medicine.medical_treatment medical oncologists chemotherapy Medical Oncology 03 medical and health sciences 0302 clinical medicine Treatment complications prevention Japan vaccine Neoplasms Surveys and Questionnaires Influenza Human medicine Humans Oncologists Chemotherapy business.industry Incidence (epidemiology) Vaccination Epidemiology and Prevention Cancer General Medicine medicine.disease Discontinuation 030104 developmental biology Oncology Influenza Vaccines 030220 oncology & carcinogenesis Emergency medicine Original Article Female influenza business |
| Zdroj: | Cancer Science |
| ISSN: | 1349-7006 1347-9032 |
| DOI: | 10.1111/cas.14742 |
| Popis: | This study aimed to clarify the attitude of oncologists toward influenza vaccination and the current situation and issues regarding influenza vaccination for patients on chemotherapy in Japan. A web‐based survey of medical oncologists certified by the Japanese Society of Medical Oncology was conducted between November 1 and December 31, 2019. Of the 1369 medical oncologists who were invited to participate, 415 (30.3%) responded to our survey. The questionnaire comprised 4 sections: “oncologist characteristics,” “oncologist attitude toward influenza vaccines and the current status of influenza vaccination for cancer patients undergoing chemotherapy,” “incidence of influenza infection and associated treatment complications,” and “treatment policy for influenza infection.” In total, 153 (36.9%) physicians replied that they did not actively encourage influenza vaccination for patients undergoing chemotherapy. The primary reasons given were lack of evidence (48/153, 31.4%) and uncertainty of appropriate timing (46/153, 30.1%). There was diverse variation in the timing of vaccination and in the levels of encouragement based on the cancer location and medication type. Two hundred eighty‐three (68.2%) oncologists reported that their cancer patients had experienced influenza infection while undergoing chemotherapy, and 169 (40.7%) responded that their patients had experienced an administration delay or discontinuation of medication because of influenza infection. Our surveillance revealed some oncologists considered evidence regarding the administration of influenza vaccine to cancer patients undergoing chemotherapy (particularly the optimal timing and level of recommendation by cancer location and medication) to be lacking. It also exposed the adverse impact of influenza infection in cancer patients. This survey aimed to clarify the current issues regarding influenza vaccination for patients on chemotherapy in Japan. There was a diverse variation in the timing of vaccination and encouragement based on the type of cancer and medication. There was substantial adverse impact of influenza infection such as discontinuation of chemotherapy on patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text